Abbott Laboratories(NYSE:ABT) reported its second-quarter 2025 results on July 17, 2025, posting 7.5% organic sales growth (excluding COVID testing), 12% medical device growth, and adjusted EPS of $1.

The Iowa Republican spoke in support of the bill passed early Thursday making cuts to foreign aid and public broadcasting.

Discover Abbott Laboratories' Q2 2025 highlights: resilience drives high single-digit growth, double-digit EPS, and pipeline innovations.

Abbott warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 ...

Medical Devices achieved strong double-digit growth, while the Diagnostics segment in China saw ongoing pressure. These 10 stocks could mint the next wave of millionaires › Abbott Laboratories ...

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

Last year, 1.14 million tourists visited Nepal, and the government has projected up to 10% increase in tourist arrivals this ...

As part of the arrangement, Baidu will introduce thousands of its Apollo Go autonomous vehicles on Uber’s platform in areas ...

Australian Prime Minister Anthony Albanese visited a panda breeding facility in the final stages of an extended state visit ...

The National Institutes of Health is in the process of suspending funding for 40 experiments because of fears that the research might be dangerous, according to a draft memo.